Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 41 of 6351
-
New drug combo aims to outperform standard therapy for advanced colorectal cancer
Disease control Recruiting nowThis study adopts a randomized, open-label, positive-controlled, multicenter design, aiming to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and bevacizumab versus standard therapy as first-line treatment for advanced colorectal cancer, and to exp…
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat brain tumors
Disease control Recruiting nowThis phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide is in a class of medications called alkyl…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could an antibody boost chemo for tough blood cancers?
Disease control Not yet recruitingThis phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune ce…
Phase 2/3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
Disease control Not yet recruitingThis clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype non-small cell lung cancer (NSCLC) in adults. It will also…
Phase 2/3 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Triple-Drug combo tackle breast cancer brain metastases?
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of adding the anti-angiogenic agent anlotinib to the combination of the CDK2/4/6 inhibitor Culmerciclib and endocrine therapy in patients with HR+/HER2- breast cancer and brain metastases. Eligible patients present with newly di…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new drug curb COPD Flare-Ups?
Disease control Recruiting nowThe study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Could a common supplement slow Alzheimer's decline?
Disease control Recruiting nowThe goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside. The main questions it aims to answer are: * Does drug n…
Phase 2 • Sponsor: Haukeland University Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can an experimental immunotherapy boost the power of standard bladder cancer treatment?
Disease control Recruiting nowThis is a multicenter, randomized, Double-blind phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus Placebo Combined with BCG in patients with high-risk BCG-naive Papillary-Only non-muscle-invasive blad…
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a targeted radiation boost slow advanced lung cancer?
Disease control Not yet recruitingLung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumo…
Phase 3 • Sponsor: Trans Tasman Radiation Oncology Group • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new PET tracer spot liver cancer more clearly?
Diagnosis Recruiting nowThis is a diagnostic study. This clinical trial aims to evaluate the diagnostic performance and safety of the novel radiotracer 18F-X12 in patients with hepatocellular carcinoma (HCC), and to provide evidence supporting a new approach for its early diagnosis, accurate staging and…
Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Can a weekly shot replace daily insulin for diabetes?
Disease control Recruiting nowThis study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 stud…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a weekly shot tame blood sugar in type 2 diabetes?
Disease control Recruiting nowThis study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutid…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
One-Day brain zaps: a new hope for stubborn depression?
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression. Treatment-resistant depression is depression that has not improved enough aft…
Sponsor: Mclean Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new pill ease the burden of heart failure with preserved pumping?
Disease control Recruiting nowThis is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejectio…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Can a new shot tame severe asthma attacks?
Disease control Not yet recruitingThe purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people w…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a JAK inhibitor bring back hair in kids with severe alopecia?
Disease control Recruiting nowAlopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body. Some treatment options are available for adults and adolescents…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Can a new drug boost chemotherapy for a rare cancer?
Disease control Not yet recruitingThis trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of adva…
Phase 3 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New quadrivalent meningitis vaccine aims to shield China's youngest from deadly infection
Vaccine Recruiting nowThe purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after …
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Sep 10, 2026 02:00 UTC
-
Can a new weekly shot boost weight loss beyond current therapies?
Disease control Not yet recruitingThe study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a weekly shot help tackle obesity in type 2 diabetes?
Disease control Not yet recruitingThe study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC